VERTEX PHARMACEUTICALS INC / MA Accumulated Other Comprehensive Income
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Accumulated Other Comprehensive Income of $48.50 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-04
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $48.50M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $24.80M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$15.90M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$64.50M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | $48.50M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $24.80M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | -$15.90M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | -$64.50M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | -$101.10M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $68.10M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $127.80M 10-K · filed 2026-02-13 | |
| 2024-09-30 | $28.80M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $22.50M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $17.30M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | -$14.30M 10-K · filed 2025-02-13 | |
| 2023-09-30 | -$3.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$39.80M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | -$13.10M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $800.00K 10-K · filed 2024-02-15 | |
| 2022-09-30 | $97.60M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $57.50M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $11.30M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $15.90M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $11.54M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | -$25.16M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | -$33.30M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | -$68.50M 10-K · filed 2022-02-09 | -$68.48M 10-K · filed 2021-02-11 |
| 2020-09-30 | -$40.98M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | -$14.12M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $13.38M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | -$1.97M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $18.85M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | -$3.20M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $6.00M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $659.00K 10-K · filed 2020-02-13 | |
| 2018-09-30 | $307.00K 10-Q · filed 2018-10-25 | |
| 2018-06-30 | -$4.61M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | -$39.74M 10-Q · filed 2018-04-27 | |
| 2018-01-01 | -$10.62M 10-K · filed 2019-02-13 | |
| 2017-12-31 | -$11.57M 10-K · filed 2019-02-13 | |
| 2017-09-30 | -$25.13M 10-Q · filed 2017-10-30 | |
| 2017-06-30 | -$21.75M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $16.02M 10-Q · filed 2017-04-28 | |
| 2016-12-31 | $21.17M 10-K · filed 2018-02-15 | |
| 2016-09-30 | -$3.85M 10-Q · filed 2016-10-31 | |
| 2016-06-30 | -$3.39M 10-Q · filed 2016-08-01 | |
| 2016-03-31 | -$4.90M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $1.82M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $1.51M 10-Q · filed 2016-10-31 | |
| 2015-06-30 | -$1.71M 10-Q · filed 2016-08-01 | |
| 2015-03-31 | $791.00K 10-Q · filed 2016-05-03 | |
| 2014-12-31 | $917.00K 10-Q · filed 2016-10-31 | |
| 2014-09-30 | $1.16M 10-Q · filed 2015-10-30 | |
| 2014-06-30 | -$23.00K 10-Q · filed 2015-08-04 | |
| 2014-03-31 | -$297.00K 10-Q · filed 2015-05-04 | |
| 2013-12-31 | -$306.00K 10-K · filed 2016-02-16 | |
| 2013-09-30 | -$550.00K 10-Q · filed 2014-11-06 | |
| 2013-06-30 | -$1.23M 10-Q · filed 2014-07-31 | |
| 2013-03-31 | -$1.15M 10-Q · filed 2014-05-05 | |
| 2012-12-31 | -$550.00K 10-K · filed 2016-02-16 | |
| 2012-09-30 | -$416.00K 10-Q · filed 2012-11-06 | |
| 2012-06-30 | -$673.00K 10-Q · filed 2012-08-08 | |
| 2012-03-31 | -$628.00K 10-Q · filed 2012-05-10 | |
| 2011-12-31 | -$1.05M 10-K · filed 2013-03-01 | |
| 2011-09-30 | -$945.00K 10-Q · filed 2011-11-03 | |
| 2011-06-30 | -$707.00K 10-Q · filed 2011-08-09 | |
| 2011-03-31 | -$633.00K 10-Q · filed 2011-05-06 | |
| 2010-12-31 | -$1.07M 10-K · filed 2012-02-22 | |
| 2010-09-30 | -$677.00K 10-Q · filed 2010-10-28 | |
| 2010-06-30 | -$558.00K 10-Q · filed 2010-08-03 | |
| 2010-03-31 | -$1.08M 10-Q · filed 2010-05-03 | |
| 2009-12-31 | -$640.00K 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |